{
    "Trade/Device Name(s)": [
        "EGENS Pregnancy Test Midstream I",
        "EGENS Pregnancy Test Midstream II"
    ],
    "Submitter Information": "Nantong Egens Biotechnology Co., Ltd.",
    "510(k) Number": "K232864",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150022"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCX"
    ],
    "Summary Letter Date": "January 26, 2024",
    "Summary Letter Received Date": "December 27, 2023",
    "Submission Date": "December 26, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human Chorionic Gonadotropin (HCG) Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Human Chorionic Gonadotropin (hCG)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow chromatographic immunoassay"
    ],
    "Methodologies": [
        "Immunochromatographic assay"
    ],
    "Submission Type(s)": [
        "Test",
        "Strip test",
        "Cassette",
        "Dipstick"
    ],
    "Document Summary": "FDA 510(k) summary for EGENS Pregnancy Test Midstream I and II qualitative lateral flow immunoassay for detection of hCG in urine to aid early pregnancy detection",
    "Indications for Use Summary": "Qualitative detection of human chorionic gonadotropin (hCG) in urine as an aid in early detection of pregnancy, in some cases as early as five days before expected period",
    "fda_folder": "Clinical Chemistry"
}